Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
Inclusion Criteria:
Exclusion Criteria:
Antioch, California 94509, United States
San Leandro, California 94578, United States
Walnut Creek, California 94598, United States
Washington D.C., District of Columbia 20010, United States
Altamonte Springs, Florida 32701, United States
Worcester, Massachusetts 01608, United States
Columbia, Missouri 65203, United States
The Bronx, New York 10461, United States
The Bronx, New York 10461, United States
Cleveland, Ohio 44106, United States
Philadelphia, Pennsylvania 19114, United States
Buenos Aires, Buenos Aires C1426ANZ, Argentina
Capital Federal, Buenos Aires C1280AEB, Argentina
Capital Federal, Buenos Aires C1405BWU, Argentina
Capital Federal, Buenos Aires C1406FWY, Argentina
Capital Federal, Buenos Aires C1408INH, Argentina
Buenos Aires, 1437, Argentina
Buenos Aires, C1405DCS, Argentina
Waratah, New South Wales 2298, Australia
Lademannbogen 8, Free and Hanseatic City of Hamburg 22339, Germany
Lohmuehlstr.5, Free and Hanseatic City of Hamburg 20099, Germany
Robert-Koch-Allee 2, Gauting 82131, Germany
Woehrendamm 80, Grosshansdorf 22927, Germany
Sudendstrasse 32, Karlshure 76147, Germany
Via Palermo, Catania 95122, Italy
Via Albertoni, Mantova 46100, Italy
West Smithfield, London EC1A 7BE, United Kingdom